


IFa



IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE

AUG 16 2007

Serial No. : 10/535,000

Applicants : Masakazu HATANO et al.

Filed : May 16, 2005

For : THERAPEUTIC AGENT FOR
GLAUCOMA COMPRISING Rho
KINASE INHIBITOR AND
β-BLOCKER

Art Unit : 1618

Examiner : Zohreh FAY

Docket No. : 05318/HG

Confirm No. : 1933

Customer No. : 01933

Express Mail Mailing Label
No. : EM 155 716 570 US
Date of Deposit: August 16, 2007
I hereby certify that this paper is
being deposited with the United States
Postal Service "Express Mail Post
Office to Addressee" service under
37 CFR 1.10 with sufficient postage
on the date indicated above and is
addressed to:
MAIL STOP AMENDMENT
Commissioner for Patents.
P.O. Box 1450
Alexandria, VA 22313-1450

Dorothy DeFrancesco
Dorothy DeFrancesco

In the event that this Paper is late
filed, and the necessary petition
for extension of time is not filed
concurrently herewith, please consider
this as a Petition for the requisite
extension of time, and to the extent
not tendered by Form PTO-2038 attached
hereto, authorization to charge the
extension fee, or any other fee
required in connection with this
Paper to Account No. 06-1378.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

MAIL STOP AMENDMENT

S I R :

Submitted concomitantly herewith are the following:

- (1) A copy of a Supplementary Partial European Search Report, which issued in the counterpart European application;
- (2) IDS Forms. It is respectfully requested that initialed copies of the enclosed IDS Forms be returned to the undersigned to indicate that the publications listed therein have been considered and made of record; and

(3) Copies of the non-U.S. patent documents cited in said IDS Forms.

Each of the cited publications in the enclosed Search Report is considered relevant or material to the patentability of the present claims in view of the citation thereof in said Search Report.

Said Search Report is in English, thereby satisfying the requirements for a concise explanation of relevance for the publications cited therein.

The following publication, which was cited in the enclosed Supplementary Partial European Search Report, was cited in the INFORMATION DISCLOSURE STATEMENT dated June 27, 2005:

HONJO MEGUMI et al., "Effects of Rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility," Investigative Ophthalmology & Visual Science, Association for Research in Vision, Vol. 42, No. 1, January 2001, pp. 137-144.


The following is a copending related application: Serial No. 10/525,986 (published as US 2005/0245509).

The enclosed IDS Forms include publications cited in application Serial No. 10/525,986.

Further submitted herewith is a corrected Sheet 2 of 2 of Form PTO/SB/08B dated June 27, 2005, which serves to correct a typographical error in the author's name of the first cited publication, namely "UEHARA, M. et al." was replaced with --UEHATA, M. et al.--.

Please substitute the enclosed Sheet 2 of 2 of Form PTO/SB/08B dated June 27, 2005 for the Sheet 2 of 2 of Form PTO/SB/08B filed on June 27, 2005.

Respectfully submitted,


RICHARD S. BARTH
REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN & CHICK, P.C.
220 FIFTH AVENUE, 16th FLOOR
NEW YORK, NEW YORK 10001-7708
Tel. Nos. (212) 319-4900
 (212) 319-4551/Ext. 219
Fax No. (212) 319-5101
E-Mail Address: BARTH@FHGC-LAW.COM
RSB/ddf

Encs.: (1) copy of Supplementary Partial European Search Report dated June 4, 2007
(2) IDS Forms
(3) copies of non-U.S. documents cited on the enclosed IDS Forms

Please type a plus sign (+) inside this box →

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

IDS FORM		O I P E AUG 16 2007 INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/535,000
				Filing Date	May 16, 2005
				First Named Inventor	Masakazu HATANO
				Group Art Unit	1618
				Examiner Name	Zohreh FAY
Sheet	1	of	2	Attorney Docket Number	05318/HG

U.S. PATENT DOCUMENTS

Exam. Inits ¹	Cite No ²	Document Number	Kind Code ³	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
		2005/0245509 4,952,581	A1	NAKAJIMA et al. BITO et al.	11-03-2005 08-28-1990	

FOREIGN PATENT DOCUMENTS

Exam. Inits ¹	Cite No ²	Offc ³	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶
/G.H./		WO	00/57914	A1	SANTEN PHARMACEUTICAL CO LTD	10-05-2000		a
/G.H./		WO	00/25771	A1	SYNPHORA AB	05-11-2000		
/G.H./		WO	90/02553	A1	PHARMACIA AB	03-22-1990		
/G.H./		EP	308135	A2	K. K. UENO SEIYAKU	03-22-1989		
/G.H./		WO	94/06433	A1	ALLERGAN INC	03-31-1994		
/G.H./		EP	639563	A2	ALCON LAB INC	02-22-1995		
/G.H./		WO	00/09162	A1	SENJU PHARMACEUTICAL CO	02-24-2000		a
/G.H./		WO	98/06433 abstract only	A1	YOSHITOMI PHARMACEUTICAL IND	02-19-1998		a

Examiner Signature	/Gigi Huang/	Date Considered	11/20/2008
--------------------	--------------	-----------------	------------

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.

DATE: August 16, 2007

a ENGLISH-LANGUAGE ABSTRACT ENCLOSED

*Please type a plus sign (+) inside this box →

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

IDS FORM INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/535,000
		Filing Date	May 16, 2005
		First Named Inventor	Masakazu HATANO
		Group Art Unit	1618
		Examiner Name	Zohreh FAY
Sheet	2	of	2
		Attorney Docket Number	05318/HG

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ³
/G.H./		ABATE M.A. et al., "Effect of Naproxen and Sulindac on Blood Pressure Response to Atenolol," <u>DICP - ANNALS OF PHARMACOTHERAPY</u> , Vol. 24, no. 9, 1990, pp. 810-813	
/G.H./		ZHOU YAN et al., "Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Ab ₄ by Inhibiting Rho," <u>Science</u> , Vol. 302, no. 5648, 14 November 2003, pp. 1215-1217	
/G.H./		HONJO et al., "Effects of Protein Kinase Inhibitor, HAL077, on Intraocular Pressure and Outflow Facility in Rabbit Eyes," <u>Archives of Ophthalmology</u> , Vol. 119, no. 8, August 2001, pp. 1171-1178	
/G.H./		DATABASE WPI Week 200060, Derwent Publications ltd., London, GB; AN 2000-628321 of WO 00/57914 (Santen Pharmaceutical Co., Ltd.; Oct. 5, 2002)	
/G.H./		CLARK A.F. et al., "Advances in Glaucoma Therapeutics," <u>Expert Opinion of Emerging Drugs</u> , 2002, United Kingdom, Vol. 7, no. 1, May 2002, pp. 141-163	
Examiner Signature		/Gigi Huang/	Date Considered 11/20/2008

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE: August 16, 2007

Substitute for Form 1449A/PTO				Application Number	10/535,000
				Filing Date	MAY 16, 2005
				First Named Inventor	Masakazu HATANO
				Group Art Unit	1618
				Examiner Name	Zohreh FAY
Sheet	2	of	2	Attorney Docket Number	05318/HG

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/G.H./		UEHATA, M. et al., "Calcium Sensitization of Smooth Muscle Mediated by a Rho-Associated Protein Kinase in Hypertension," <u>Nature</u> , (1997), <u>389</u> , pp. 990 to 994.	
not considered		Naohiko KOMI et al., "Ryokunaisho to Ryokunaisho Chiryo Yakuzaishi (Ryokunaisho no Seisan ni osoi Doushinsaku no Kangaerunokata)," ("Some Practical Aspect in Medical Therapy") Ganka, (2002), <u>44</u> (11), pp. 1443 to 1448.	
not considered		Tatsuro EIKUCHI, "I. Ryokunaisho no Yakuhyaku, Ryaku 2. Ryokunaisho Chiryo Yakuzaishi o Kohan shinkei Sogaiyaku β Shadanyaku," ("β-Adrenergic Antagonists") Ganka, (2002), <u>44</u> (11), pp. 1458 to 1463.	
/G.H./ abstract only		Ikuko AZUMA et al., "Effects of Bumazosin Hydrochloride Ophthalmic Solution in Combination with Timolol Maleate Ophthalmic Solution in Patients with Open-Angle Glaucoma and Ocular Hypertension-Comparison with Dipivefrin Hydrochloride Ophthalmic Solution," <u>The Journal of the Eye</u> , (2002), <u>19</u> (2), pp. 261 to 266.	
/G.H./ abstract only		Yuichiro SANO et al., "Effect and Safety of Combined Therapy with Betaxolol and isopropyl Unoprostone," <u>The Journal of the Eye</u> , (2000), <u>17</u> (5), pp. 687 to 690.	
/G.H./		Hideki TOKUSHIGE, "ROCK Sogaiyaku to Ryokunaisho" ("ROCK Inhibitor and Glaucoma"), <u>BIO Clinica</u> , (2002), <u>17</u> (13), pp. 1191 to 1194.	
/G.H./		HOYNG, P.F.J. et al., "Pharmacological Therapy for Glaucoma," <u>Drugs</u> , (2000), <u>59</u> (3), pp. 411 to 434.	
/G.H./		Megumi HONJO et al., "Effects of Rho-Associated Protein Kinase Inhibitor Y-27632 on Intraocular Pressure and Outflow Facility," <u>Invest. Ophthalmol. & Vis. Sci.</u> , Vol. 42, No. 1 (2001), pp. 137-144.	
/G.H./		P. Vasantha RAO et al., "Modulation of Aqueous Humor Outflow Facility by the Rho Kinase-Specific Inhibitor Y-27632," <u>Invest. Ophthalmol. & Vis. Sci.</u> , Vol. 42, No. 5 (2001), pp. 1029-1037.	
Examiner Signature	/Gigi Huang/	Date Considered	11/20/2008

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.